Sagimet Biosciences Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Sagimet Biosciences Inc. (SGMT) reported Increase (Decrease) in Prepaid Expense and Other Assets of $826.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $529.00K, a 1411.43% increase year-over-year.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $297.00K, a 56.77% decline year-over-year.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $283.00K.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $825.00K, a 80.85% decline year-over-year.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.83M, a 36500.00% increase from fiscal 2024.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $5.00K, a 99.47% decline from fiscal 2023.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $952.00K.
- Sagimet Biosciences Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.44M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $826.00K 10-Q · filed 2026-08-11 | $1.11M derived: sum of 3 quarters · filed 2026-08-11 | $1.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $297.00K 10-Q · filed 2026-05-12 | $580.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.41M derived: sum of 3 quarters · filed 2026-05-12 | $1.44M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.11M derived: sum of 2 quarters · filed 2026-03-11 | $1.14M derived: sum of 3 quarters · filed 2026-08-11 | $1.83M 10-K · filed 2026-03-11 |
| 2025-09-30 | $825.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $860.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.55M 10-Q · filed 2025-11-13 | -$1.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $722.00K 10-Q · filed 2026-08-11 | -$2.53M derived: sum of 3 quarters · filed 2026-08-11 | $1.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $687.00K 10-Q · filed 2026-05-12 | -$2.57M derived: sum of 2 quarters · filed 2026-05-12 | $1.74M derived: sum of 3 quarters · filed 2026-05-12 | $1.33M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$3.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.05M derived: sum of 2 quarters · filed 2026-03-11 | $645.00K derived: sum of 3 quarters · filed 2026-03-11 | $5.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.90M derived: sum of 2 quarters · filed 2025-11-13 | $3.26M 10-Q · filed 2025-11-13 | $3.82M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.05M 10-Q · filed 2025-08-13 | -$486.00K derived: sum of 3 quarters · filed 2025-08-13 | $279.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$640.00K 10-Q · filed 2025-05-08 | -$78.00K derived: sum of 2 quarters · filed 2025-05-08 | $687.00K derived: sum of 3 quarters · filed 2025-05-08 | $275.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.33M derived: sum of 2 quarters · filed 2025-03-12 | $915.00K derived: sum of 3 quarters · filed 2025-03-12 | $952.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $765.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $353.00K derived: sum of 2 quarters · filed 2024-11-14 | $390.00K 10-Q · filed 2024-11-14 | $280.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$412.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$375.00K 10-Q · filed 2024-08-14 | -$485.00K derived: sum of 3 quarters · filed 2024-08-14 | -$364.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $37.00K 10-Q · filed 2024-05-15 | -$73.00K derived: sum of 2 quarters · filed 2024-05-15 | $48.00K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $11.00K derived: sum of 2 quarters · filed 2024-03-25 | -$1.44M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.33M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$1.45M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |